|
private:otologicpharmaceutics
|
5890463
|
Feb 27th, 2023 12:00AM
|
Otologic Pharmaceutics
|
105
|
1.00
|
Open
|
Pharmaceutical Manufacturing
|
Feb 26th, 2023 10:05PM
|
Feb 26th, 2023 10:05PM
|
Otologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing function resulting from chronic and age-related hearing loss. Currently, no pharmacological treatment for hearing loss is available. The status of OPI’s programs is as follows:
•NHPN-1010 (HPN-07 plus N-acetylcysteine, NAC) completed two Phase 1 safety/pharmacokinetic studies in healthy volunteers, and is anticipated to enter a Phase 2 trial in collaboration with Oblato.
•Preclinical siRNA program for regeneration of auditory sensory epithelia (hair cells) in the cochlea lost as a result of age-related hearing loss or chronic NIHL, has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss.
Press Releases:
https://www.prnewswire.com/news-releases/oblato-biotech-company-acquires-hearing-loss-drug-discovered-by-hough-ear-institute-scientists-301003204.html
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Feb 23rd, 2023 12:00AM
|
Otologic Pharmaceutics
|
105
|
1.00
|
Open
|
Pharmaceutical Manufacturing
|
Feb 23rd, 2023 11:53AM
|
Feb 23rd, 2023 11:53AM
|
Otologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing function resulting from chronic and age-related hearing loss. Currently, no pharmacological treatment for hearing loss is available. The status of OPI’s programs is as follows:
•NHPN-1010 (HPN-07 plus N-acetylcysteine, NAC) completed two Phase 1 safety/pharmacokinetic studies in healthy volunteers, and is anticipated to enter a Phase 2 trial in collaboration with Oblato.
•Preclinical siRNA program for regeneration of auditory sensory epithelia (hair cells) in the cochlea lost as a result of age-related hearing loss or chronic NIHL, has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss.
Press Releases:
https://www.prnewswire.com/news-releases/oblato-biotech-company-acquires-hearing-loss-drug-discovered-by-hough-ear-institute-scientists-301003204.html
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Feb 10th, 2023 12:00AM
|
Otologic Pharmaceutics
|
103
|
1.00
|
Open
|
Pharmaceutical Manufacturing
|
Feb 10th, 2023 01:50PM
|
Feb 10th, 2023 01:50PM
|
Otologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing function resulting from chronic and age-related hearing loss. Currently, no pharmacological treatment for hearing loss is available. The status of OPI’s programs is as follows:
•NHPN-1010 (HPN-07 plus N-acetylcysteine, NAC) completed two Phase 1 safety/pharmacokinetic studies in healthy volunteers, and is anticipated to enter a Phase 2 trial in collaboration with Oblato.
•Preclinical siRNA program for regeneration of auditory sensory epithelia (hair cells) in the cochlea lost as a result of age-related hearing loss or chronic NIHL, has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss.
Press Releases:
https://www.prnewswire.com/news-releases/oblato-biotech-company-acquires-hearing-loss-drug-discovered-by-hough-ear-institute-scientists-301003204.html
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Jan 20th, 2023 12:00AM
|
Otologic Pharmaceutics
|
101
|
1.00
|
Open
|
Pharmaceuticals
|
Jan 20th, 2023 10:14AM
|
Jan 20th, 2023 10:14AM
|
Otologic Pharmaceutics, Inc. (OPI) was founded in 2009 to develop novel therapeutics to prevent and restore hearing loss. OPI has a clinical-stage program for an oral medication for residual hearing loss protection in cochlear implants with secondary indications in Meniere’s Disease and tinnitus and preclinical programs focused on the restoration of hearing function resulting from chronic and age-related hearing loss. Currently, no pharmacological treatment for hearing loss is available. The status of OPI’s programs is as follows:
•NHPN-1010 (HPN-07 plus N-acetylcysteine, NAC) completed two Phase 1 safety/pharmacokinetic studies in healthy volunteers, and is anticipated to enter a Phase 2 trial in collaboration with Oblato.
•Preclinical siRNA program for regeneration of auditory sensory epithelia (hair cells) in the cochlea lost as a result of age-related hearing loss or chronic NIHL, has demonstrated restoration of auditory function in animal models of acute and chronic hearing loss.
Press Releases:
https://www.prnewswire.com/news-releases/oblato-biotech-company-acquires-hearing-loss-drug-discovered-by-hough-ear-institute-scientists-301003204.html
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Dec 3rd, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 3rd, 2020 12:09PM
|
Dec 3rd, 2020 12:09PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Dec 2nd, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 2nd, 2020 02:30PM
|
Dec 2nd, 2020 02:30PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Dec 1st, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Dec 1st, 2020 01:57PM
|
Dec 1st, 2020 01:57PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Nov 30th, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 29th, 2020 08:01PM
|
Nov 30th, 2020 02:49PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Nov 28th, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 28th, 2020 03:36PM
|
Nov 28th, 2020 03:36PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|
|
private:otologicpharmaceutics
|
5890463
|
Nov 27th, 2020 12:00AM
|
Otologic Pharmaceutics
|
41
|
1.00
|
Open
|
Pharmaceuticals
|
Nov 27th, 2020 12:02PM
|
Nov 27th, 2020 12:02PM
|
Otologic Pharmaceutics is a clinical stage company developing new treatments for the global problem of hearing loss and hearing-related diseases. We work closely with our collaborators at the Hough Ear Institute and Oblato.
|
Open
|
|
Open
|
|
Oklahoma City
|
Oklahoma
|
US
|
73104
|
|
Otologic Pharmaceutics
|
|
Health Care Equipment & Services
|